Patient population:
Adults and pediatric patients with COVID-19 infection, who are admitted on an inpatient floor or to the intensive care unit.

Key points:
Details regarding isolation/precautions, personal protective equipment, patient movement, family/visitor policy, and cleaning/disinfection can be found here.

Clinical symptoms:
Range from asymptomatic, uncomplicated upper respiratory tract viral infection to pneumonia, acute respiratory distress syndrome (ARDS), sepsis, and septic shock (Table 1)

Diagnosis:
See current COVID-19 testing recommendations.

Treatment:
Based on data from several randomized control trials, Remdesivir may provide a modest benefit in a subgroup of patients hospitalized with COVID-19. See further details regarding patient populations (see below) and Table 2.

Table 1. Potential Treatment Recommendations by Severity of Disease for Patients 18 Years or Older
Most COVID-19 therapeutics have not been studied in children under 18. The below treatment recommendations may apply to some children, however, should be addressed on a case-by-case basis and discussed with Pediatric Infectious Diseases. See specific sections for further details

<table>
<thead>
<tr>
<th>Disease severity</th>
<th>Potential Treatment Recommendations (per ID consult discretion based on details in Table 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No supplemental oxygen</td>
<td>• Supportive care</td>
</tr>
<tr>
<td></td>
<td>• Monoclonal Antibodies or Remdesivir (3 days) may be an option in certain high-risk patients (see eligibility criteria in Table 2) admitted for reasons other than COVID-19 who have mild to moderate symptoms of COVID-19. Depending on supply, monoclonal antibodies are preferred over remdesivir in patients meeting criteria for monoclonal antibody use.</td>
</tr>
<tr>
<td>Low flow supplemental oxygen</td>
<td>• Supportive care</td>
</tr>
<tr>
<td></td>
<td>• Dexamethasone (Exception: Minimal supplemental oxygen (1-2 L) in adults with &lt;7 days of symptoms—uncertain benefit)</td>
</tr>
<tr>
<td></td>
<td>• Remdesivir (5 days)</td>
</tr>
<tr>
<td>High flow supplemental oxygen or non-invasive mechanical ventilation</td>
<td>• Supportive Care</td>
</tr>
<tr>
<td></td>
<td>• Dexamethasone</td>
</tr>
<tr>
<td></td>
<td>• Tocilizumab</td>
</tr>
<tr>
<td></td>
<td>• Remdesivir (5 days) (uncertain benefit)</td>
</tr>
<tr>
<td>Mechanical ventilation or ECMO</td>
<td>• Supportive care</td>
</tr>
<tr>
<td></td>
<td>• Dexamethasone</td>
</tr>
<tr>
<td></td>
<td>• Tocilizumab</td>
</tr>
</tbody>
</table>
Table 2: Therapeutic agents dosing, duration, and details for treatment of COVID-19

<table>
<thead>
<tr>
<th>Therapeutic Agents</th>
<th>Dosing &amp; Duration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Remdesivir (5-day regimen)</strong></td>
<td></td>
<td>• Please page 30780 (adult) or 36149 (pediatrics) for approval prior to first dose of remdesivir between 7 AM and 11 PM (7 days a week).</td>
</tr>
<tr>
<td></td>
<td>Adult dosing: 200 mg IV load, then 100 mg IV q24h</td>
<td></td>
</tr>
</tbody>
</table>
|  | Pediatric dosing: 3.5 kg to <40 kg: 5 mg/kg IV load, then 2.5 mg/kg q24h 
≥40 kg: 200 mg IV load, then 100 mg IV q24h | |
|  | Duration: 5 days or until hospital discharge whichever comes first. Patients started on remdesivir and progress to requiring higher level of oxygen support (i.e., mechanical ventilation) should still complete a course of remdesivir | |
| Guidelines for Use: Patients should meet criteria a & b. | | • ID consult is recommended for the following reasons: 
  o Pediatric patient 
  o Question about whether remdesivir should be initiated/continued 
  o Patient does not meet criteria for remdesivir but unique clinical circumstances warrant ID evaluation for treatment 
  o Patient/family request |
| a. Laboratory confirmed SARS-CoV-2 infection by PCR from nasopharyngeal or respiratory sample and ≤14 days of symptoms | | • CrCl <30 mL/min is not a contraindication to remdesivir. The risk of cyclodextrin accumulation to a toxic level with 5 days of therapy is small & benefit likely outweighs risk |
| b. Severe COVID-19 on admission or during hospitalization: Requires supplemental oxygen, high-flow nasal cannula*, or non-invasive mechanical ventilation* | | • Increased LFTs: daily monitoring of hepatic function is recommended. The risk of hepatotoxicity with a baseline AST/ALT >5x ULN is not known due to patient exclusion from clinical trials; weigh benefit versus risk |
| Patients < 18 years | | • Pregnancy: Use of remdesivir should not be withheld in pregnant patients if otherwise indicated per criteria on this page. |
| Remdesivir is generally indicated for patients 12-17 years and ≥40 kg who meet the above criteria. For patients <12 years or <40 kg, remdesivir is available through EUA; discuss with Pediatric Infectious Diseases. | | • Patients <12 years AND ≥3.5 kg to <40 kg can qualify under EUA: 
  o Healthcare Providers must review Fact Sheet for Healthcare Providers 
  o Patient/caregiver should be informed of potential risks/benefits and extent to which such risks/benefits are unknown 
  o Patient/caregiver should be informed of alternative treatments 
  o Provide the patient/caregiver a copy of the Fact Sheet for Parents and Caregivers 
  o Document in the medical chart the information discussed/provided to the patient/caregiver |

*HFNC and NIMV are included as possible indications for remdesivir, but it is uncertain if remdesivir confers a clinical benefit among patients requiring this level of O2 support

Patients < 18 years

Remdesivir is generally indicated for patients 12-17 years and ≥40 kg who meet the above criteria. For patients <12 years or <40 kg, remdesivir is available through EUA; discuss with Pediatric Infectious Diseases.
<table>
<thead>
<tr>
<th>Therapeutic Agents</th>
<th>Dosing &amp; Duration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Patients 18 years and older:</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 1. **Recommended in patients with COVID-19 who require mechanical ventilation or ECMO** | Adult dosing: 6 mg PO or IV q24h | Weigh risks/benefits of use on a case-by-case basis in patients with:  
- Active bacterial or fungal infection  
- Diabetic ketoacidosis  
- Baseline immunosuppression  

Not recommended in the following patients:  
- Not requiring supplemental oxygen. (In RECOVERY, those had a trend towards worse outcomes).  
- No longer COVID-19 PCR positive, but remain intubated. (In RECOVERY, patients were randomized after admission; the risk/benefit of alternative approaches later in the disease course is unknown).  

**Pregnancy, breastfeeding:**  
- Consult OB for gestational age of viability. Alternatives may be prednisone 40 mg PO daily or hydrocortisone 80 mg IV BID.  

Dexamethasone is a CYP3A4 substrate, as such drug interactions should be assessed prior to use. Alternatives less prone to interactions are prednisone 40 mg PO daily, methylprednisolone 32 mg IV daily, or hydrocortisone 80 mg IV BID.  

**Potential adverse events:**  
- Increased risk for infection  
- Hyperglycemia  
- Peripheral edema  
- Increased appetite  
- Insomnia, irritability, delirium  

In the setting of a dexamethasone shortage, an equivalent total daily dose of an alternative glucocorticoid to dexamethasone 6 mg daily can be used (e.g., methylprednisolone 32 mg (<40 kg: 0.8 mg/kg) daily or prednisone 40 mg (<40 kg: 1 mg/kg) daily) |
| 2. **Recommended for patients on supplemental oxygen. The benefit of dexamethasone is uncertain in adults on minimal levels of supplemental oxygen (1-2L) with <7 days of symptoms. Decisions should be individualized in such patients with consideration of disease severity in conjunction with risks and benefits of glucocorticoid therapy.** | Pediatric dosing*: 0.15 mg/kg/dose IV q24h (max: 6 mg/dose) |          |
| **Duration:** Maximum 10 days, or until discharge | Shorter duration is reasonable to consider in patients who have improved rapidly or are experiencing adverse events from steroids. The median duration of therapy in the RECOVERY trial was 6 days. |          |
|                      |                   |          |
| **Patients <18 years:** |                   |          |
| Patients <18 years were not represented in the RECOVERY RCT and the mean participant age was 66 years. It is not known if the benefit of dexamethasone will extend to children with COVID-19 who require oxygen, or if there is even the potential for harm, as seen in adults who did not require oxygen. However, it is reasonable to consider dexamethasone for children who require mechanical ventilation, or high levels of oxygen support (e.g., high-flow oxygen or noninvasive ventilation), particularly if they are rapidly progressing toward mechanical ventilation. Recommend consultation with Pediatric Infectious Diseases. | |          |
|                      |                   |          |

*Pediatric dosing is based on extrapolation from the adult dose and the RECOVERY protocol but has not been established for COVID-19.
<table>
<thead>
<tr>
<th>Therapeutic Agents</th>
<th>Dosing &amp; Duration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SARS-COV-2 Neutralizing Antibodies</strong>&lt;br&gt;Available via FDA issued Emergency Use Authorization&lt;br&gt;Sotrovimab</td>
<td>Adult and Pediatric dosing (≥12 years AND ≥40 kg)&lt;br&gt;&lt;br&gt;*Serostatus per spike protein antibody. Order SARS-CoV-2 (COVID-19) Total Antibody, Spike (RBD) Qualitative</td>
<td>ID approval is required. ID consultation is recommended and can only be ordered by ID consultants</td>
</tr>
<tr>
<td>Eligibility Criteria&lt;br&gt;Patients with mild or moderate COVID-19 who meet criteria #1-5:&lt;br&gt;1. ≥12 years AND ≥40 kg&lt;br&gt;2. Admitted for a reason not related to COVID&lt;br&gt;3. No requirement for supplemental oxygen (or no increase from baseline supplemental oxygen)&lt;br&gt;4. Symptoms ≤7 days&lt;br&gt;5. Any of the following&lt;br&gt;   a. B-cell depleting therapy (e.g., rituximab, ocrelizumab, ofatumumab, alemtuzumab, venetoclax)&lt;br&gt;   b. BTKi therapy (e.g., ibrutinib, acalabrutinib)&lt;br&gt;   c. HCT / CAR-T within 6 months of transplant or cGHVD/immunosuppression which would be expected to reduce vaccine effectiveness&lt;br&gt;   d. Multiple myeloma on therapy&lt;br&gt;   e. CLL on therapy&lt;br&gt;   f. Solid organ transplant&lt;br&gt;      i. Within one year of transplant and seronegative*&lt;br&gt;      ii. Greater than one year from transplant AND 65 years or older AND seronegative*&lt;br&gt;      iii. Lung transplant recipients seronegative at any age*&lt;br&gt;   g. Severe primary immunodeficiency not expected to respond to vaccination&lt;br&gt;   h. Other patients with severe immunodeficiency to be reviewed on an individual basis by Infectious Diseases/Antimicrobial Stewardship</td>
<td>Note: Sotrovimab is not authorized for use in patients &lt;12 years old and/or &lt;40 kg</td>
<td>At the discretion of the ID consultant, monoclonal antibody therapy may be given for patients not meeting the eligibility criteria listed but who are still deemed high risk for progression to severe disease.</td>
</tr>
<tr>
<td>Sotrovimab 500 mg IV x1</td>
<td>Healthcare Providers must review Fact Sheet for Healthcare Providers: Sotrovimab</td>
<td>Healthcare Providers must provide recipients with the Fact Sheet for Patients/Caregivers and communicate the following information to the recipients: Sotrovimab</td>
</tr>
<tr>
<td></td>
<td>1. FDA has authorized emergency use of Sotrovimab, which is not an FDA-approved therapy</td>
<td>1. The patient or caregiver has the option to accept or refuse administration</td>
</tr>
<tr>
<td></td>
<td>2. The significant known and potential risks and benefits of the therapy and the extent to which such risks and benefits are unknown</td>
<td>3. Information on available alternative treatments and the risks and benefits of those alternatives.</td>
</tr>
<tr>
<td>Therapeutic Agents</td>
<td>Dosing &amp; Duration</td>
<td>Comments</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>Remdesivir (3-day regimen)</strong></td>
<td></td>
<td>- Please page 30780 (adult) or 36149 (pediatric) for approval prior to first dose of remdesivir between 7 AM and 11 PM (7 days a week).</td>
</tr>
</tbody>
</table>

**Note** the eligibility criteria below. This 3-day regimen is indicated for patients with mild-moderate COVID-19 (not hypoxic). This indication is based on the PINETREE study (doi: 10.1056/nejmoa2116846).

**Eligibility Criteria**

Patients with mild or moderate COVID-19 who meet criteria #1-4 AND one of criteria #5-10:

1. No requirement for supplemental oxygen (or no increase from baseline supplemental oxygen)
2. Symptoms ≤7 days
3. Received no more than 1 dose of any COVID-19 vaccine OR unlikely to respond to vaccination (due to moderate-to-severe immunocompromise)*
4. Not a candidate for monoclonal antibodies (see above)
5. ≥60 years old
6. Moderate-to-severe immunocompromise*
7. Pregnancy
8. ≥18 years old AND one of the following:
   a. Chronic lung disease: chronic obstructive pulmonary disease, moderate-to-severe asthma, cystic fibrosis, pulmonary fibrosis
   b. Hypertension: systemic or pulmonary
   c. Cardiovascular or cerebrovascular disease: coronary artery disease, congenital heart disease, heart failure, cardiomyopathy, history of stroke
   d. Diabetes mellitus: Type 1 or 2
   e. Obesity (BMI ≥30)
   f. Chronic kidney disease: any stage
   g. Chronic liver disease
   h. Sickle cell disease
9. 12-17 years with obesity (weight ≥95thile for age)
10. ≤17 years with underlying medical condition and provider concern for progression to severe COVID-19; case-by-case, consult pediatric infectious diseases

*Moderate or Severe Immunocompromise
   i. SOT on immunosuppressive medications
   ii. Active malignancy and receiving chemotherapy
   iii. Hematopoietic stem cell transplant in last 2 years or receiving immunosuppressive therapy
   iv. Autoimmune diseases requiring immunosuppressive therapy
   v. Advanced or untreated HIV infection
   vi. Primary immunodeficiency not expected to respond to vaccination

**Adult dosing:**

- 200 mg IV load, then 100 mg IV q24h

**Pediatric dosing:**

- 3.5 kg to <40 kg:
  - 5 mg/kg IV load, then 2.5 mg/kg q24h
- ≥40 kg:
  - 200 mg IV load, then 100 mg IV q24h

**Duration:**

- 3 days or until hospital discharge whichever comes first.

- CrCl <30 mL/min is not a contraindication to remdesivir. The risk of cyclodextrin accumulation to a toxic level with 5 days of therapy is small & benefit likely outweighs risk

- Increased LFTs: daily monitoring of hepatic function is recommended. The risk of hepatotoxicity with a baseline AST/ALT >5x ULN is not known due to patient exclusion from clinical trials; weigh benefit versus risk

- Patients <12 years AND ≥3.5 kg to <40 kg can qualify under EUA with Pediatric Infectious Disease Consult:
  - Healthcare Providers must review Fact Sheet for Healthcare Providers
  - Patient/caregiver should be informed of potential risks/benefits and extent to which such risks/benefits are unknown
  - Patient/caregiver should be informed of alternative treatments
  - Provide the patient/caregiver a copy of the Fact Sheet for Parents and Caregivers
  - Document in the medical chart the information discussed/provided to the patient/caregiver
**Therapeutic Agents**

<table>
<thead>
<tr>
<th>Tocilizumab</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ID APPROVAL NEEDED, ID consult is recommended for all patients with critical COVID</strong></td>
</tr>
</tbody>
</table>

**Recommend Tocilizumab (in addition to dexamethasone) in patients:**
1. Newly on mechanical ventilation (<48 hours)
2. On high flow supplemental oxygen or noninvasive mechanical ventilation

**Tocilizumab is NOT recommended in the following scenarios:**
1. Patients requiring lower levels of respiratory support than high flow support, noninvasive ventilation, or mechanical ventilation.
2. High concern for systemic bacterial or fungal co-infection
3. Receiving mechanical ventilation for longer than 48 hours
4. Patients who significantly improve with the initiation of enhanced oxygen support or corticosteroids; monitoring such patients for 12-24 hours is reasonable
5. Unlikely to survive >48 hours
6. Receiving baricitinib* (see comment)

**Recommendations are primarily based on preliminary findings from the REMAP-CAP and RECOVERY trials (see references 14 and 16). Pediatric patients were not represented in these trials. It is not known if the benefit will extend to children with COVID-19. Recommend consultation with Infectious Diseases.**

**Dosing & Duration**

**Dose rounding currently built into Epic order. Doses should be rounded to nearest available full vial (80 mg, 200 mg, 400 mg vials)**

**Adult Dosing (≥18 years):**
8 mg/kg (max: 800 mg/dose)

**Pediatric Dosing (2 to 17 years):**

- <30 kg: 12 mg/kg
- ≥30 kg: 8 mg/kg (max: 800 mg/dose)

**Duration:**
One dose

**There are no data to inform risk vs. benefit of a second dose. Based on local experience a second dose is NOT recommended.**

**Comments**

**Pregnancy and Nursing Mothers:**
- Maternal-Fetal Medicine at Michigan Medicine has endorsed the use of tocilizumab in pregnancy
- Tocilizumab may be harmful to newborns, and mothers should stop breastfeeding if receiving tocilizumab but may resume after discontinuation and discussion with provider
- *Tocilizumab benefit has been shown in studies with concomitant corticosteroid therapy. The combination of tocilizumab + baricitinib has not been rigorously studied and both the safety and efficacy of this combination is unclear. Thus, when tocilizumab is administered, it should be in combination with dexamethasone or an equivalent corticosteroid. Prior use of baricitinib is not a contraindication to using tocilizumab

**Serious adverse events:**
- Gastrointestinal perforation
- Anemia
- Hepatitis
- Infusion reaction
- Neutropenia
- Infection

Healthcare Providers must review FDA Fact Sheet for Health Care Providers

Healthcare Providers must provide recipients with the Fact Sheet for Patients/Caregivers and communicate the following information to the recipients:
1. FDA has authorized emergency use of Tocilizumab for patients 2 years and older with COVID-19, which is not an FDA-approved indication for use
2. The patient or caregiver has the option to accept or refuse administration of Tocilizumab
3. The significant known and potential risks and benefits of Tocilizumab and the extent to which such risks and benefits are unknown
4. Information on available alternative treatments and the risks and benefits of those alternatives.

Do not use (therapies without any supportive evidence and/or associated with potential harm): hydroxychloroquine, hydroxychloroquine + azithromycin, lopinavir/ritonavir, nitazoxanide, oseltamivir, baloxavir, interferon, ribavirin, IVIG
Antibiotic Management for Pneumonia in PUI and Confirmed COVID-19 Patients

Recommendations:

1. In patients admitted with suspected COVID-19 pneumonia (testing pending), decisions whether to initiate antibiotic therapy should be based on guidance provided in the institutional pneumonia treatment and procalcitonin usage guidelines.
2. Continuation/initiation of antibiotic therapy solely due to confirmation of COVID-19 pneumonia is not indicated as described below.
3. In patients with confirmed COVID-19 pneumonia, community-onset bacterial co-infection is uncommon, even in critically ill patients, and elevated procalcitonin levels are not reliably associated with bacterial infection, especially in the setting of concomitant renal dysfunction. Empiric antibiotic therapy should generally be discontinued once a patient is confirmed COVID-19 positive but may be indicated in patients with leukocytosis and/or hemodynamic instability. De-escalation/discontinuation of antibiotics should be considered based on clinical and microbiological data. Note that an extended duration of fevers is typical in COVID-19 patients.
4. In patients who test negative for COVID-19 pneumonia, antibiotic therapy should be based on guidance provided in the institutional pneumonia treatment and procalcitonin usage guidelines.

Reports thus far have not identified unusual associations between COVID-19 infection and bacterial co-infection. Additionally, no unique association with resistant pathogens, including MRSA or Pseudomonas, has been made.

In an observational analysis by Somers et al of 154 patients with severe COVID-19 infection requiring mechanical ventilation at Michigan Medicine:
- 40% developed a bacterial superinfection, with 32% developing bacterial pneumonia. The median time to development of infection was 8-10 days after initiation of mechanical ventilation.

In a review of studies reporting bacterial co-infections in patients with COVID-19, Lansbury et al reported that the proportion of co-infection in ICU patients was 14%, compared to a proportion of 4% in studies which grouped ICU and floor-status together. Timing of onset of infection was not reported. Similarly, Vaughn et al reported that 3.5% of all patients hospitalized with COVID-19 had a community-onset bacterial co-infection and that 11% of patients admitted directly to the ICU had a community-onset bacterial co-infection.

In the study of adult patients by Zhou et al:
- 15% of hospitalized COVID-19 patients developed a secondary bacterial infection (definition: clinical symptoms or signs of pneumonia or bacteremia with a positive culture).
- The median time to secondary bacterial infection was 17 days (13 to 19 days).
- Of all COVID-19 patients in their cohort, 79% had a WBC <10.
- Only 1% of survivors developed a secondary bacterial infection, yet the median duration of fever in survivors was 12 days and cough persisted for 19 days. Thus, ‘just in case’ treatment of bacterial infection can result in prolonged durations of therapy.

Data in pediatric patients are limited, but one small study (Xia et al.) suggests that procalcitonin may be higher in children with COVID-19, regardless of suspected bacterial superinfection. Decisions about antibiotic management for children should continue to be guided by clinical judgment.

Adult pneumonia treatment guidelines are summarized here, and adult and pediatric pneumonia treatment guidelines are available in their entirety at:
- Pneumonia Treatment (Adult)
- Community-Acquired Pneumonia Treatment (Pediatrics)
- Procalcitonin Use Guidelines
Procalcitonin

- Although PCT levels should not be used in isolation to decide whether to initiate antibiotics in patients with suspected bacterial pneumonia, **bacterial co-infection is unlikely in a confirmed COVID-19 patient with a low procalcitonin (<0.25), and antibiotics can be safely withheld**. In addition, PCT levels >0.25 are not uncommon in patients with COVID-19 pneumonia, and do not appear to be a reliable marker of bacterial superinfection. Importantly, patients with CKD and AKI have falsely elevated PCT levels, and as such PCT is not reliable in such settings. Procalcitonin should also NOT be routinely used to *extend* treatment duration.

**Adult Pneumonia Treatment Summary Recommendations**

<table>
<thead>
<tr>
<th>Indication</th>
<th>1st Line Empiric Therapy (see guidelines for alternatives)</th>
<th>Duration of Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathway A</strong> – Inpatient community-acquired with no risk factors</td>
<td><strong>Ampicillin-sulbactam</strong> 3 g IV q6h + Azithromycin 500 mg IV/PO x1 day, then 250 mg q24h x4 days</td>
<td><strong>Uncomplicated pneumonia:</strong> 5 days for patients who defervesce within 72 hours and have no more than 1 sign of CAP instability at the time of antibiotic discontinuation</td>
</tr>
</tbody>
</table>
| **Pathway B** -Community onset pneumonia with risk factors for drug resistant pathogens (see risk factors below) | **Cefepime** 2 g IV q8h (+ **Tobramycin** IV if admitted to ICU) + **Vancomycin*** IV (see nomogram)  
*Discontinue vancomycin if no evidence of MRSA colonization/infection (negative MRSA nasal swab or respiratory culture). | **Uncomplicated pneumonia:** 7 days |
| **Pathway C** Hospital-acquired Pneumonia  
Ventilator-associated pneumonia | **Cefepime** 2 g IV q8h (+ **Tobramycin** IV if admitted to ICU) + **Vancomycin*** IV (see nomogram)  
*Discontinue vancomycin if no evidence of MRSA colonization/infection (negative MRSA nasal swab or respiratory culture). | **Uncomplicated pneumonia:** 7 days |

**PATHWAY B RISK FACTORS**

- History of infection or colonization with Pseudomonas spp., MRSA, or pathogens resistant to standard CAP therapy (ampicillin-sulbactam or ceftriaxone) within previous 12 months
- Severe community-acquired pneumonia (septic shock OR requiring mechanical ventilation OR high clinical concern for needing ICU care\(^3\)), AND meeting 1 of the following criteria:
  - Hospitalization for at least 48 hours AND use of any intravenous antibiotic, fluoroquinolone, or linezolid within previous 90 days OR
  - Immunocompromised, defined as:
    - AIDS (CD4 <200)
    - Neutropenia (ANC <1000)
    - Kidney or liver or heart transplant recipient within previous 1 year
    - Solid organ transplant recipient treated for rejection within previous 6 months
    - Lung transplant recipient
    - Allogeneic stem cell transplant within previous 1 year or those with chronic GVHD
    - Autoimmune disorders on biologic agents (TNFα inhibitors, rituximab, etc.)

**Concomitant use of NSAIDs and/or ACE-I/ARBs:**

There are conflicting theories regarding the risk and benefit of non-steroidal anti-inflammatory drugs (NSAIDs) or angiotensin converting enzyme inhibitors/ angiotensin II receptor blockers (ACE-I/ARBs) in patients with COVID-19 infection. Currently, there are no robust data demonstrating beneficial or adverse outcomes with use of these drugs in COVID-19 infections or specifically in COVID-19 infected patients taking these medications for cardiovascular disease. The American Heart Association, American College of Cardiology, and Heart Failure Society of America do not recommend stopping ACE-I or ARBs in COVID-19 infected patients. In addition, a clinical trial (NCT04312009) is investigating whether adjunctive ARB therapy can improve outcomes in COVID-19 patients. Pending this data, we do not endorse stopping or starting such therapies solely because of COVID-19 infection.
References:
The recommendations in this guide are meant to serve as treatment guidelines for use at Michigan Medicine facilities. If you are an individual experiencing a medical emergency, call 911 immediately. These guidelines should not replace a provider's professional medical advice based on clinical judgment, or be used in lieu of an Infectious Diseases consultation when necessary. As a result of ongoing research, practice guidelines may from time to time change. The authors of these guidelines have made all attempts to ensure the accuracy based on current information, however, due to ongoing research, users of these guidelines are strongly encouraged to confirm the information contained within them through an independent source.

If obtained from a source other than med.umich.edu/asp, please visit the webpage for the most up-to-date document.